Valsartan/Hydrochlorothiazide: A review of its use in the management of hypertension

Drugs

Volumn 66, Issue 14, 2006, Pages 1881-1901

  Wagstaff, Antona J ^a,b   Cohn, J N ^c   Frost, L ^d   Kahan, T ^e   Kjeldsen, S E ^f   Schwartz, G L ^g   Staessen, J A ^h  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e DANDERYD HOSPITAL   (Sweden)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; VALSARTAN;

AFRICAN AMERICAN; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; REVIEW; SYNCOPE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; TETRAZOLES; TREATMENT OUTCOME; VALINE;

ANGINA; SYNCOPE;

EID: 33750190467     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666140-00011     Document Type: Review

References (92)

1. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
2. Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens 2005 Sep; 7 (9): 505-12
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15; 365: 217-23
4. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003 May 21; 289 (19): 2534-44
5. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drug 2005; 5 (3): 171-83
6. Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999 May; 57 (5): 751-5; discussion 756-8
7. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62 (13): 1983-2005
8. Criscione L, de Gasparo M, Bühlmayer P, et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993 Oct; 110 (2): 761-71
9. Verheijen I, Fierens FLP, DeBacker JP, et al. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type I receptors. Fundam Clin Pharmacol 2000; 14 (6): 577-85
10. Novartis Pharmaceuticals UK Ltd. Co-Diovan 80/12.5 mg, 160/12.5 mg/ 160/25 mg tablets; UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Apr 26]
11. Saito F, Kimura G. Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 1996; 27: 914-8
12. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001 Jul; 29: 270-9
13. Plum J, Bünten B, Németh R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998 Dec; 9: 2223-34
14. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6): 672-8
15. Thürmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998 Nov 10; 98 (19): 2037-42
16. Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004 Jun 2; 43 (11): 2116-23
17. Munakata M, Nagasaki A, Nunokawa T, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004 Nov; 17 (11): 1050-5
18. Shargorodsky M, Leibovitz E, Lubimov L, et al. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens 2002 Dec; 15 (12): 1087-91
19. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003 Feb; 16 (2): 123-8
20. Watanabe H, Nakagawa K, Kakihana M. Effects of valsartan on endothelial function and aortic stiffness in hypertensive patients with stroke [abstract no. P563]. Eur Heart J 2003 Aug; 24 (Suppl.): 93
21. Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 1-7
22. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST Study. Clin Ther 2005 May; 27 (5): 578-87
23. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997 Feb; 37 (2): 101-7
24. Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002 Jul; 40: 28-34
25. Delles C, Klingbeil AU, Schneider MP, et al. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003 Dec; 16 (12): 1030-5
26. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005 Mar; 28 (3): 209-14
27. Ohbayashi Y, Tsutamoto T, Sakaguchi T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003 Dec; 42 (Suppl. 1): S71-4
28. Malacco E, Piazza S, Scandiani L, et al. Effects of valsartan/ hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther 2004 May; 21 (3): 149-61
29. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press 2003; 12 (Suppl. 2): 29-34
30. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002 Jun; 58: 177-80
31. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004 Jan; 17 (1): 77-81
32. Rinder MR, Spina RJ, Peterson LR, et al. Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults. Am J Physiol Regul Integr Comp Physiol 2004 Apr 29; 287 (2): R360-8
33. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004 Jan; 43: 4-9
34. Hoogerbrugge N, de Groot E, de Heide LHM, et al. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Neth J Med 2002 Oct; 60 (9): 354-61
35. Maitland-van der Zee AH, Turner ST, Schwartz GL, et al. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005 Aug; 18 (8): 1077-83
36. Schwartz GL, Turner ST, Chapman AB, et al. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002 Nov; 62 (5): 1718-23
37. Carretta R, Trenkwalder P, Martinez F, et al. Pulse pressure responses in patients treated with valsartan and hydrochlorothiazide combination therapy. J Int Med Res 2003; 31 (5): 370-7
38. Weisser B, Vetter H, Mengden T. Decreased blood pressure, pulse pressure and heart rate under treatment with valsartan alone or combined with hydrochlorothiazide: results of an open trial in 11447 hypertensives [in German]. Dtsch Med Wochenschr 2003 Mar 14; 128 (11): 541-4
39. Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004 Jun; 26 (6): 855-65
40. Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52 (2): 115-20
41. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73-86
42. Novartis Pharmaceuticals Corporation. Diovan HCT® valsartan and hydrochlorothiazide, USP; combination tablets 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, 320mg/25mg; US prescribing information. East Hanover (NJ): Novartis, 2006
43. Novartis Pharmaceuticals Canada Inc. Diovan-HCT (valsartan and hydrochlorothiazide) tablets, 80mg/12.5mg, 160mg/12.5mg, and 160mg/25mg; Canadian prescribing information. Dorval, Quebec: Novartis, 2004
44. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997 Jan; 27 (1): 59-71
45. Taeschner W, Vo.zeh S. Appendix A: pharmacokinetic drug data. In: Speight TM, Holford NHG, editors. Avery's Drug Treatment. 4th ed. Auckland: Adis International Limited, 1997: 1629-64
46. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
47. Kalbag J, Prasad P, Redalieu E, et al. Plasma concentrations and antihypertensive effect of 10 to 160 mg doses of valsartan (VAL) in hypertensive patients [abstract no. PPDM 8140]. Pharm Res 1994; 11 (10 Suppl.): S367
48. Weir SJ, Dimmitt DC, Lanman RC, et al. Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. Biopharm Drug Dispos 1998; 19: 365-71
49. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998 May; 19: 237-44
50. Prasad P, Mangat S, Choi L, et al. Effect of renal function on the pharmacokinetics of valsartan. Clin Drug Invest 1997; 13 (4): 207-14
51. Leidig MF, Delles C, Kuchenbecker C, et al. Pharmacokinetics of valsartan in hypertensive patients on long-term haemodialysis. Clin Drug Invest 2001; 21 (1): 59-66
52. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997 Sep; 62 (3): 272-8
53. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-31
54. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004 Jun 19; 363: 2049-51
55. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998 Dec; 12 (12): 861-6
56. Hall WD, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest 1998 Sep; 16 (3): 203-10
57. Hedner T, Reimund B, Le Breton S, et al. Valsartan and hydrochlorothiazide combination therapy (320/12.5 mg and 320/25 mg) provides effective blood pressure control in hypertensive patients inadequately controlled by monotherapy. American Society of Hypertension 21st annual scientific meeting and exposition, May 16-20 2006, New York; Abstract no. P-165 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
58. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005 Jul; 27 (7): 1013-21
59. Mallion J-M, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003; 12 (Suppl. 1): 36-43
60. Pool J, Glazer R, Weinberger M, et al. Treatment with valsartan and hydrochlorothiazide alone and in combination at doses up to 320/25 mg provides effective blood pressure control in hypertensive patients. American Society of Hypertension 21st annual scientific meeting and exposition, May 16-20 2006, New York; Abstract no. P-179 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
61. Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press 2001; 10 (4): 230-7
62. Franco RJS, Goldflus S, McQuitty M, et al. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press 2003; 12 (Suppl. 2): 41-7
63. Palatini P, Malacco E, Fogari R, et al. A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens 2001 Sep; 19 (9): 1691-169
64. Weir MR, Ferdinand KC, Flack JM, et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005 Sep; 46 (3): 508-13
65. Ruilope LM, Heintz D, Brandão AA, et al. 24-hour ambulatory blood-pressure effects of valsartan & hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. Blood Press Monit 2005 Apr; 10 (2): 85-91
66. Zanchetti A, Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
67. Pool J, Glazer R, Graff A, et al. Long-term combination treatment with valsartan and hydrochlorothiazide (320/12.5 mg and 320/25 mg) provides effective blood pressure control and is well-tolerated in hypertensive patients. American Society of Hypertension 21st annual scientific meeting and exposition, May 16-20 2006, New York; Abstract no. P-180 [online]. Available from URL: www.ash-us.org [Accessed 2006 May 17]
68. Weir MR, Aknay N, Purkayastha D, et al. Antihypertensive efficacy of valsartan and valsartan/HCTZ in elderly hypertensives: exploratory analyses of nine clinical trials. American Society of Hypertension 21st annual scientific meeting and exposition, May 16-20 2006, New York; Abstract no. P-231 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
69. Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison of the antihypertensive effects of the candesartan 8 mg-hydrochlorothiazide 12.5 mg combination (C8+H) vs the valsartan 80 mg-hydrochlorothiazide 12.5 mg combination (V80+H) in patients with essential hypertension resistant to monotherapy [abstract no. P2.367]. J Hypertens 2004 Jun; 22 (Suppl. 2): S254-5
70. Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003 Nov; 25 (11): 2765-80
71. White W, Punzi H, Neutel J, et al. Telmisartan plus hydrochlorothiazide (80/25 mg) has a greater antihypertensive effect than valsartan plus hydrochlorothiazide (160/25 mg) in patients with stage 1 and 2 hypertension [abstract no. P254]. Am J Hypertens 2005 May; 18 (5 pt 2): 97A
72. [plus poster presented at the 20th Annual Scientific Meeting of the American Society of Hypertension; 2005 Dec 10-13; San Fransisco (CA)]
73. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005 Nov; 18 (11): 1482-8
74. Palatini P, Mugellini A, Spagnuolo V, et al. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit 2004 Apr; 9 (2): 91-7
75. Malacco E, Palatini P, Val-Combo Investigators. The efficacy and tolerability of valsartan-based versus lisinopril-based treatment in patients with mild to moderate hypertension: the Val-Combo study [abstract no. P728]. J Hypertens 2004 Feb; 22 (Suppl. 1): 197S
76. Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000 Jul; 20 (1): 1-7
77. Sever P. VALUE: analysis of results [letter]. Lancet 2004 Sep 11; 364: 933-4
78. Hermida RC, Calvos C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003 Sep; 42 (3): 283-90
79. Morgan TO, Anderson A. Different drug classes have variable effects on blood pressure depending on the time of day. Am J Hypertens 2003 Jan; 16: 46-50
80. Chalmers J, Guidelines Sub-Committee. 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. Blood Press 1999; 8 (Suppl.1): 9-43
81. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-72
82. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004 Mar 13; 328 (7440): 634-40
83. Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003 Oct; 21 (10): 1779-86
84. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct 29; 366: 1545-53
85. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006 Jun 6; 174 (12): 1737-42
86. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7
87. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404
88. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans. Arch Intern Med 2003 Mar 10; 163 (5): 525-41
89. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. NEJM 2006 Jun 1; 354 (22): 2368-74
90. Palatini P, Dorigatti F, Mugellini A, et al. Ambulatory versus clinic blood pressure for the assessment of antihypertensive efficacy in clinical trials: insights from the Val-Syst study. Clin Ther 2004 Sep; 26 (9): 1436-45
91. Goodman R, Lanese JW, Singson CR, et al. Symptom assessment and quality of life in hypertensive patients following modification of antihypertensive therapy to a regimen containing valsartan. J Outcomes Res 2004; 8: 1-14
92. Kjeldsen SE, Os I, Høieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5 (1): 17-22